
Blue Water Life Science Advisors
Blue Water Life Science Advisors focuses its investments on life sciences companies, particularly those involved in technology platforms, diagnostics, and devices, and may also include emerging pharmaceutical companies. Their strategy involves a concentrated, research-driven approach to public equities in these sectors, seeking high-conviction positions with strong growth prospects, and they also engage in venture capital investments at various stages.
75% of their portfolio is in Healthcare. They made 1 investments in the last 12 months. Their most common stage is series-e (50% of deals). Average disclosed round size is $77.5M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$159.3M
Top Stage
Series E
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Growth | $55M | Jun 2025 | |
| Series E | $35M | Jun 2022 | |
| Series E | $135M | Jun 2022 | |
| VVizgen | Series C | $85.2M | Jun 2022 |
Top Co-Investors
Last updated: 16 April 2026